New Zealand defers decision on gout medicine

11 August 2021 - Deborah Wilkes

Premium

New Zealand's Medicines Classification Committee (MCC) has deferred a decision on an application to change the status of allopurinol for preventing gout, but has made recommendations on proposals involving choline salicylate, hyaluronidase and ibuprofen.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: